Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosis

Boddy, S., Islam, M. orcid.org/0000-0002-2296-0120, Moll, T. et al. (17 more authors) (2022) Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosis. Brain Communications, 4 (2). fcac069. ISSN 2632-1297

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited
Keywords: Metabolome; amyotrophic lateral sclerosis; Mendelian randomization; isoleucine; vitamin B12
Dates:
  • Accepted: 15 March 2022
  • Published (online): 17 March 2022
  • Published: 17 March 2022
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:
FunderGrant number
ACADEMY OF MEDICAL SCIENCESSBF005\1064
MOTOR NEURONE DISEASE ASSOCIATIONAllen/Oct15/956-799
National Institute for Health ResearchNIHRDH-IS-BRC-1215-20017
Academy of Medical SciencesAMS-SBF005\1064
Depositing User: Symplectic Sheffield
Date Deposited: 04 May 2022 16:17
Last Modified: 04 May 2022 16:17
Status: Published
Publisher: Oxford University Press
Refereed: Yes
Identification Number: https://doi.org/10.1093/braincomms/fcac069
Related URLs:

Download

Export

Statistics